News & Views - Page 24 of 53 - Telix Pharmaceuticals Limited

HRH Princess Astrid of Belgium visits Telix’s New European Manufacturing Facility in Brussels South

Telix has welcomed Her Royal Highness, Princess Astrid, Princess of Belgium to Telix Manufacturing Solutions (TMS), the Company’s recently inaugurated production facility, in Brussels South (Seneffe) in the Wallonia region of Belgium.

Telix collaborates with Eckert & Ziegler and RefleXion Medical to Expand Treatment Options for Prostate Cancer Patients

Telix, Eckert & Ziegler, and RefleXion Medical today announced a comprehensive collaboration agreement to jointly develop a new concept – Satellite Hot Labs (SHLs). SHLs are designed specifically for radiolabeling, quality control and storage of molecular targeting radiotracers, referred to as BioGuides, that are used in biology-guided radiotherapy (BgRT) to direct the radiation beam to indicated solid tumor cancers.

Telix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM

Telix today announces presentations featuring the Company’s theranostic programs at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Vienna from 9 – 13 September 2023.

Join Telix at EANM 2023 to explore personalised diagnostics in urological cancers

Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company

Telix today announces its financial results for the half-year ended 30 June 2023. All figures are in AUD$ unless otherwise stated.

Telix Half-Year Results 2023 and Investor Call / Webcast Notification

Telix today advises that it will release its financial results for the half-year ended 30 June 2023 on Wednesday 23 August 2023.

First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients

Telix today announces that a first patient has been dosed in China in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11), for the imaging of prostate cancer using positron emission tomography (PET).

First Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma

Telix today announces that a first patient has been dosed in a Phase I study of the Company’s investigational therapy TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) in combination with post-surgical standard of care treatment in patients with newly diagnosed glioblastoma, the most common and aggressive form of primary brain cancer.

Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow

Telix today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 June 2023 (Q2 2023). All figures are in AUD$ unless otherwise stated and provided on an unaudited basis.

First Patient Dosed in STARSTRUCK Study

Telix today announces that the first patient has been dosed in a Phase I study of the Company’s investigational targeted radiation therapy, TLX250, in combination with a Merck KGaA, Darmstadt, Germany (Merck) DNA-dependent protein kinase (DNA-PK) inhibitor candidate, peposertib (M3814). The study is being conducted in patients with solid tumours expressing carbonic-anhydrase IX (CAIX), a potential pan-cancer target.